Search research articles
Contact Us
Filters
Showing results (1-10 of 20) with videos related to
Page
of 2
Sort By:
Expert Opinion on Therapeutic Targets
|
December 22, 2017
BCL6 as a therapeutic target for lymphoma
Rebecca J Leeman-Neill, Govind Bhagat
Current Hematologic Malignancy Reports
|
June 27, 2018
Pathogenesis of Enteropathy-Associated T Cell Lymphoma
Udit Chander, Rebecca J Leeman-Neill, Govind Bhagat
Journal of Immunology (Baltimore, Md. : 1950)
|
October 24, 2018
The Common Key to Class-Switch Recombination and Somatic Hypermutation: Discovery of AID and Its Role in Antibody Gene Diversification
Rebecca J Leeman-Neill, Junghyun Lim, Uttiya Basu
Advances in Immunology
|
May 19, 2024
AID in non-Hodgkin B-cell lymphomas: The consequences of on- and off-target activity
Rebecca J Leeman-Neill, Govind Bhagat, Uttiya Basu
Archives of Pathology & Laboratory Medicine
|
June 5, 2026
KMT2A Amplification in Mixed-Phenotype Acute Leukemia: Immunophenotyping, Cytogenomic Features, and Clinical Correlation
Madhulatha Pantrangi, Paul Dylan Barone, Rebecca J Leeman-Neill, et al.
British Journal of Haematology
|
November 17, 2015
Proliferation centres of chronic lymphocytic leukaemia/small lymphocytic lymphoma have enhanced expression of MYC protein, which does not result from rearrangement or gain of the MYC gene
Sarah E Gibson, Rebecca J Leeman-Neill, Sarika Jain, et al.
The American Journal of Dermatopathology
|
June 21, 2016
Fatal Case of Primary Cutaneous Aggressive T-Cell Lymphoma Switching From a CD4+ to a CD8+ Phenotype: Progressive Disease With Bexarotene and Romidepsin Treatment
William T Johnson, Rebecca J Leeman-Neill, Parth Patel, et al.
Leukemia Research
|
May 4, 2019
Low-level BCR-ABL1 transcripts in individuals without overt hematologic malignancy
Rebecca J Leeman-Neill, Steven H Swerdlow, Catherine L Burnes, et al.
Molecular Cancer Therapeutics
|
July 30, 2009
Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death
Changyou Li, Yan Zang, Malabika Sen, et al.
American Journal of Hematology
|
September 1, 2020
The clinical and pathological features of plasma cell myeloma post solid organ transplantation
Kenneth Ofori, Craig R Soderquist, Vundavalli V Murty, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 20) with videos related to
Sort By:
Page
of 2
Expert Opinion on Therapeutic Targets
|
December 22, 2017
BCL6 as a therapeutic target for lymphoma
Rebecca J Leeman-Neill, Govind Bhagat
Current Hematologic Malignancy Reports
|
June 27, 2018
Pathogenesis of Enteropathy-Associated T Cell Lymphoma
Udit Chander, Rebecca J Leeman-Neill, Govind Bhagat
Journal of Immunology (Baltimore, Md. : 1950)
|
October 24, 2018
The Common Key to Class-Switch Recombination and Somatic Hypermutation: Discovery of AID and Its Role in Antibody Gene Diversification
Rebecca J Leeman-Neill, Junghyun Lim, Uttiya Basu
Advances in Immunology
|
May 19, 2024
AID in non-Hodgkin B-cell lymphomas: The consequences of on- and off-target activity
Rebecca J Leeman-Neill, Govind Bhagat, Uttiya Basu
Archives of Pathology & Laboratory Medicine
|
June 5, 2026
KMT2A Amplification in Mixed-Phenotype Acute Leukemia: Immunophenotyping, Cytogenomic Features, and Clinical Correlation
Madhulatha Pantrangi, Paul Dylan Barone, Rebecca J Leeman-Neill, et al.
British Journal of Haematology
|
November 17, 2015
Proliferation centres of chronic lymphocytic leukaemia/small lymphocytic lymphoma have enhanced expression of MYC protein, which does not result from rearrangement or gain of the MYC gene
Sarah E Gibson, Rebecca J Leeman-Neill, Sarika Jain, et al.
The American Journal of Dermatopathology
|
June 21, 2016
Fatal Case of Primary Cutaneous Aggressive T-Cell Lymphoma Switching From a CD4+ to a CD8+ Phenotype: Progressive Disease With Bexarotene and Romidepsin Treatment
William T Johnson, Rebecca J Leeman-Neill, Parth Patel, et al.
Leukemia Research
|
May 4, 2019
Low-level BCR-ABL1 transcripts in individuals without overt hematologic malignancy
Rebecca J Leeman-Neill, Steven H Swerdlow, Catherine L Burnes, et al.
Molecular Cancer Therapeutics
|
July 30, 2009
Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death
Changyou Li, Yan Zang, Malabika Sen, et al.
American Journal of Hematology
|
September 1, 2020
The clinical and pathological features of plasma cell myeloma post solid organ transplantation
Kenneth Ofori, Craig R Soderquist, Vundavalli V Murty, et al.
Page
of 2